Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENZA-p: Lu-PSMA + Enzalutamide in mCRPC
NCT04419402Phase 2Active, not recruiting
- Sponsor
- ANZUP Cancer Trials Group
- Start
- Aug 2020
- Primary completion
- Apr 2024
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lutetium lu 177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by ANZUP Cancer Trials Group. Primary endpoint: Prostate Specific Antigen Progression-Free Survival up to 4 years. Started Aug 2020; status: active, not recruiting.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04419402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04419402.